Phase Ⅱ trial of infusional fluorouracil,irinotecan,and bevacizumab for metastatic colorectal cancer:efficacy and circulating angiogenic biomarkers associated with therapeutic resistance .XELIRIbevacizumab versus FOLFIRI-bevacizumab as first-line treatmen ......